Admedus : Update on the CardioCel 3D Product Launch

Admedus Limited (ASX:AHZ) today announced that it is moving from its premarket program to an expanded access program for CardioCel® 3D to ensure that the Company gathers as much useful case data as possible before the product's commercial introduction. Admedus is already working in four key reference centers in the United States and this will increase to 10 prior to full launch later this year.

"The progress to date on CardioCel 3D has been excellent and the current user feedback from our surgeons is extremely promising," says Admedus CEO Wayne Paterson. "This is a pioneering new product - applying our proprietary ADAPT® technology - for an important market segment, and so we are making every effort to launch CardioCel® 3D right from the start in a phased and prudent way working closely with physicians."

For more information, please contact:

Admedus (ASX:AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus Website: www.admedus.com